<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="article-commentary" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">102427</article-id><article-id pub-id-type="doi">10.7554/eLife.102427</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Insight</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="sub-display-channel"><subject>Immunotherapy</subject></subj-group></article-categories><title-group><article-title>The power lies in the glycans</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Unione</surname><given-names>Luca</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8724-8783</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/><bio><p><bold>Luca Unione</bold> is in the Center for Cooperative Research in Biosciences, Basque Research and Technology Alliance, Bizkaia, Spain and the Ikerbasque, Basque Foundation for Science, Bilbao, Spain</p></bio></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Jiménez-Barbero</surname><given-names>Jesús</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5421-8513</contrib-id><email>jjbarbero@cicbiogune.es</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/><bio><p><bold>Jesús Jiménez-Barbero</bold> is in the Center for Cooperative Research in Biosciences, Basque Research and Technology Alliance, Bizkaia, Spain and the Ikerbasque, Basque Foundation for Science, Bilbao, Spain, the Department of Organic &amp; Inorganic Chemistry, Faculty of Science and Technology, University of the Basque Country, and the Centro de Investigacion Biomedica En Red de Enfermedades Respiratorias, Madrid, Spain</p></bio></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02x5c5y60</institution-id><institution>Center for Cooperative Research in Biosciences, Basque Research and Technology Alliance</institution></institution-wrap><addr-line><named-content content-type="city">Derio</named-content></addr-line><country>Spain</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01cc3fy72</institution-id><institution>Ikerbasque, Basque Foundation for Science</institution></institution-wrap><addr-line><named-content content-type="city">Bilbao</named-content></addr-line><country>Spain</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/000xsnr85</institution-id><institution>Department of Organic &amp; Inorganic Chemistry, Faculty of Science and Technology, University of the Basque Country</institution></institution-wrap><addr-line><named-content content-type="city">Leioa</named-content></addr-line><country>Spain</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0119pby33</institution-id><institution>Centro de Investigacion Biomedica En Red de Enfermedades Respiratorias</institution></institution-wrap><addr-line><named-content content-type="city">Madrid</named-content></addr-line><country>Spain</country></aff></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>20</day><month>09</month><year>2024</year></pub-date><volume>13</volume><elocation-id>e102427</elocation-id><permissions><copyright-statement>© 2024, Unione and Jiménez-Barbero</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Unione and Jiménez-Barbero</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-102427-v1.pdf"/><related-article related-article-type="commentary-article" ext-link-type="doi" xlink:href="10.7554/eLife.100083" id="ra1"/><abstract><p>Glycans play an important role in modulating the interactions between natural killer cells and antibodies to fight pathogens and harmful cells.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>glycans</kwd><kwd>natural killer cells</kwd><kwd>immunotherapy</kwd><kwd>antibodies</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Other</kwd></kwd-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Glycans play an important role in modulating the interactions between natural killer cells and antibodies to fight pathogens and harmful cells.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>Template</meta-name><meta-value>1</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text><p><bold>Related research article</bold> Kremer P, Lampros E, Blocker A, Barb A. 2024. One N-glycan regulates natural killer cell antibody-dependent cell-mediated cytotoxicity and modulates Fcγ receptor IIIa/CD16a structure. <italic>eLife</italic> <bold>13</bold>:RP100083. doi: <ext-link ext-link-type="uri" xlink:href="http://doi.org/10.7554/eLife.100083">10.7554/eLife.100083</ext-link>.</p></boxed-text><p>Since the COVID-19 pandemic, antibodies have become a household name. These Y-shaped proteins are part of the immune system and recognize, tag and neutralize pathogens, as well as cancer cells. Each tip of the Y of the antibody (the 'arms') can bind to target cells, while the vertical 'leg' of the Y communicates with other components of the immune system.</p><p>Antibodies can help neutralize harmful cells through a mechanism known as antibody-dependent cell-mediated cytotoxicity (ADCC). During this process, antibodies coating a target cell bind to Fcγ receptors on the surface of an immune cell called a natural killer cell. This event activates the natural killer cell, causing it to release molecules that kill the target cell.</p><p>For over four decades, antibodies have been successfully cloned and engineered in laboratories to make monoclonal antibodies as targeted treatments for various diseases, including cancer (<xref ref-type="bibr" rid="bib9">Sharma et al., 2023</xref>). Strengthening the interactions between Fcγ receptors and antibodies has been shown to improve the immune response through ADCC and thus represents a strategy to boost therapeutic efficacy (<xref ref-type="bibr" rid="bib5">Presta et al., 2002</xref>).</p><p>Both Fcγ receptors and antibodies are glycoproteins. These are proteins that have undergone a process called glycosylation that results in the attachment of carbohydrate chains (known as glycans). Fcγ receptors have five glycosylation sites on their extracellular portion, two of which are close to where antibodies bind (<xref ref-type="bibr" rid="bib6">Reily et al., 2019</xref>). The glycan composition at each of these sites is usually diverse. Previous research found that the specific glycan composition of natural killer cells (and possibly of their receptors) affects the potency of ADCC (<xref ref-type="bibr" rid="bib8">Rodriguez Benavente, 2024</xref>; <xref ref-type="bibr" rid="bib7">Rodriguez Benavente et al., 2023</xref>). However, so far, it has been unclear how this enhances ADCC. Now, in eLife, Paul Kremer, Elizabeth Lampros, Allison Blocker and Adam Barb at the University of Georgia report how the glycan composition at a specific glycosylation site on the Fcγ receptor modulates ADCC (<xref ref-type="bibr" rid="bib2">Kremer et al., 2024</xref>).</p><p>Kremer et al. generated a library of Fcγ receptors with various mutations to the area that binds antibodies and with different glycoforms (<xref ref-type="fig" rid="fig1">Figure 1</xref>). This allowed them to assess how individual glycans and their location within the Fcγ receptor affect the ability of natural killer cells to bind to antibodies. This exhaustive approach revealed that the glycan chain attached to the Fcγ receptor at a specific amino acid site (known as N162) is a critical mediator of the increased ADCC responses, and that shorter glycans at this site significantly increase the affinity for the antibody (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Schematic illustrating the binding affinity of Fcγ receptors and antibodies.</title><p>Natural killer cells (NK cell, purple) express Fcγ receptors on their surface (teal structures) that contain glycan units (structure made out of dots and squares). The Fcγ receptors bind to antibodies (blue and yellow Y-shaped structure) that coat target cells (pink), triggering natural killer cells to release molecules (small purple circles) that kill the target cell. A strong connection between Fcγ receptors and antibodies enhances this process, known as antibody-dependent cell-mediated cytotoxicity (ADCC). Kremer et al. show that the complexity of glycans in the Fcγ receptor affects ADCC potency. Fcγ receptors with more complex glycans (left) induce weaker ADCC than those with removed glycan units (truncated, right). In particular, the affinity between the receptor and the antibody increases with each glycan truncation step. mAb: monoclonal antibody. Figure 1 was created with <ext-link ext-link-type="uri" xlink:href="https://biorender.com/f44i414">BioRender.com</ext-link>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102427-fig1-v1.tif"/></fig><p>Next, the team evaluated how the composition of the identified glycan affects the structure and flexibility of Fcγ receptors. New experimental methodologies based on atomic resolution techniques, such as nuclear magnetic resonance, provided key structural insights into understanding the mechanisms underlying the antibody-Fcγ binding event. With the support of computer studies, Kremer et al. concluded that a unique composition of the glycan at this site enhances antibody binding by stabilizing the conformation of Fcγ required for a stronger interaction with the antibody.</p><p>The study of Kremer et al. provides the first evidence that specific glycosylation on the Fcγ receptor is responsible for a higher binding affinity between the receptor and the antibody, building on existing evidence of how antibody glycosylation affects Fcγ-binding affinity (<xref ref-type="bibr" rid="bib10">Shields et al., 2002</xref>; <xref ref-type="bibr" rid="bib1">Ferrara et al., 2011</xref>; <xref ref-type="bibr" rid="bib3">Mizushima et al., 2011</xref>). It demonstrates that Fcγ engineering is a promising strategy to promote improved ADCC responses through efforts to tune the glycan composition of natural killer cells. In that sense, natural killer cell-based immunotherapies have already shown promising outcomes in cancer treatment (<xref ref-type="bibr" rid="bib4">Page et al., 2024</xref>). The results presented by Kremer et al. indicate an unexplored avenue to improve natural killer cell-mediated immunotherapies in a variety of diseases that may eventually improve patient responses.</p></body><back><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrara</surname><given-names>C</given-names></name><name><surname>Grau</surname><given-names>S</given-names></name><name><surname>Jäger</surname><given-names>C</given-names></name><name><surname>Sondermann</surname><given-names>P</given-names></name><name><surname>Brünker</surname><given-names>P</given-names></name><name><surname>Waldhauer</surname><given-names>I</given-names></name><name><surname>Hennig</surname><given-names>M</given-names></name><name><surname>Ruf</surname><given-names>A</given-names></name><name><surname>Rufer</surname><given-names>AC</given-names></name><name><surname>Stihle</surname><given-names>M</given-names></name><name><surname>Umaña</surname><given-names>P</given-names></name><name><surname>Benz</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose</article-title><source>PNAS</source><volume>108</volume><fpage>12669</fpage><lpage>12674</lpage><pub-id pub-id-type="doi">10.1073/pnas.1108455108</pub-id><pub-id pub-id-type="pmid">21768335</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kremer</surname><given-names>P</given-names></name><name><surname>Lampros</surname><given-names>E</given-names></name><name><surname>Blocker</surname><given-names>A</given-names></name><name><surname>Barb</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>One N-glycan regulates natural killer cell antibody-dependent cell-mediated cytotoxicity and modulates Fcγ receptor IIIa/CD16a structure</article-title><source>eLife</source><volume>13</volume><elocation-id>RP100083</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.100083</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizushima</surname><given-names>T</given-names></name><name><surname>Yagi</surname><given-names>H</given-names></name><name><surname>Takemoto</surname><given-names>E</given-names></name><name><surname>Shibata-Koyama</surname><given-names>M</given-names></name><name><surname>Isoda</surname><given-names>Y</given-names></name><name><surname>Iida</surname><given-names>S</given-names></name><name><surname>Masuda</surname><given-names>K</given-names></name><name><surname>Satoh</surname><given-names>M</given-names></name><name><surname>Kato</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans</article-title><source>Genes to Cells</source><volume>16</volume><fpage>1071</fpage><lpage>1080</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2443.2011.01552.x</pub-id><pub-id pub-id-type="pmid">22023369</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Page</surname><given-names>A</given-names></name><name><surname>Chuvin</surname><given-names>N</given-names></name><name><surname>Valladeau-Guilemond</surname><given-names>J</given-names></name><name><surname>Depil</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Development of NK cell-based cancer immunotherapies through receptor engineering</article-title><source>Cellular &amp; Molecular Immunology</source><volume>21</volume><fpage>315</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1038/s41423-024-01145-x</pub-id><pub-id pub-id-type="pmid">38443448</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Presta</surname><given-names>LG</given-names></name><name><surname>Shields</surname><given-names>RL</given-names></name><name><surname>Namenuk</surname><given-names>AK</given-names></name><name><surname>Hong</surname><given-names>K</given-names></name><name><surname>Meng</surname><given-names>YG</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Engineering therapeutic antibodies for improved function</article-title><source>Biochemical Society Transactions</source><volume>30</volume><fpage>487</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1042/bst0300487</pub-id><pub-id pub-id-type="pmid">12196120</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reily</surname><given-names>C</given-names></name><name><surname>Stewart</surname><given-names>TJ</given-names></name><name><surname>Renfrow</surname><given-names>MB</given-names></name><name><surname>Novak</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Glycosylation in health and disease</article-title><source>Nature Reviews Nephrology</source><volume>15</volume><fpage>346</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1038/s41581-019-0129-4</pub-id><pub-id pub-id-type="pmid">30858582</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez Benavente</surname><given-names>MC</given-names></name><name><surname>Hughes</surname><given-names>HB</given-names></name><name><surname>Kremer</surname><given-names>PG</given-names></name><name><surname>Subedi</surname><given-names>GP</given-names></name><name><surname>Barb</surname><given-names>AW</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Inhibiting N-glycan processing increases the antibody binding affinity and effector function of human natural killer cells</article-title><source>Immunology</source><volume>170</volume><fpage>202</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1111/imm.13662</pub-id><pub-id pub-id-type="pmid">37218360</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez Benavente</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Distinct CD16a features on human NK cells observed by flow cytometry correlate with increased ADCC</article-title><source>Scientific Reports</source><volume>14</volume><elocation-id>7938</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-024-58541-6</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>P</given-names></name><name><surname>Joshi</surname><given-names>RV</given-names></name><name><surname>Pritchard</surname><given-names>R</given-names></name><name><surname>Xu</surname><given-names>K</given-names></name><name><surname>Eicher</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Therapeutic Antibodies in Medicine</article-title><source>Molecules</source><volume>28</volume><elocation-id>6438</elocation-id><pub-id pub-id-type="doi">10.3390/molecules28186438</pub-id><pub-id pub-id-type="pmid">37764213</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shields</surname><given-names>RL</given-names></name><name><surname>Lai</surname><given-names>J</given-names></name><name><surname>Keck</surname><given-names>R</given-names></name><name><surname>O’Connell</surname><given-names>LY</given-names></name><name><surname>Hong</surname><given-names>K</given-names></name><name><surname>Meng</surname><given-names>YG</given-names></name><name><surname>Weikert</surname><given-names>SHA</given-names></name><name><surname>Presta</surname><given-names>LG</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity</article-title><source>The Journal of Biological Chemistry</source><volume>277</volume><fpage>26733</fpage><lpage>26740</lpage><pub-id pub-id-type="doi">10.1074/jbc.M202069200</pub-id><pub-id pub-id-type="pmid">11986321</pub-id></element-citation></ref></ref-list></back></article>